NCT03829306 (KATIA) is a clinical trial in Advanced Breast Cancer, sponsored by Spanish Breast Cancer Research Group.

Who is sponsoring NCT03829306?

NCT03829306 is sponsored by Spanish Breast Cancer Research Group.

What condition does NCT03829306 study?

NCT03829306 studies Advanced Breast Cancer.

Is NCT03829306 still recruiting?

NCT03829306 is currently completed. Last updated 13 January 2023.

Last reviewed 2023-01-13 · How we verify

NCT03829306: KATIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

Completed Last updated 13 January 2023

What this trial tests

trial in Advanced Breast Cancer in 32 participants. Completed in 21 June 2022.

Timeline

12 June 2018

Primary endpoint
21 June 2022

21 June 2022

Quick facts

Lead sponsor	Spanish Breast Cancer Research Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	32
Start date	12 June 2018
Primary completion	21 June 2022
Estimated completion	21 June 2022
Sites	10 locations across Spain

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

Spanish Breast Cancer Research Group

Who can join

18 and older, any sex, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aim is to perform a comprehensive and integrated characterization of mechanisms of primary and acquired resistance to Kadcyla in a prospective cohort of progressive/recurrent HER2-positive breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.
Palacín-Aliana I, García-Romero N, Asensi-Puig A, Carrión-Navarro J, et al · · 2021 · cited 38× · PMID 34440110 · DOI 10.3390/biomedicines9080906

Verify or expand the search:

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other Spanish Breast Cancer Research Group trials

Trials by the same sponsor.

NCT07478939 — Study on the Level of Physical Activity in Patients Diagnosed With Breast Cancer in Spain · completed
NCT05744375 — Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab · Phase 2 · terminated
NCT05583110 — Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non · Phase 2 · terminated
NCT04293393 — Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients · Phase 2 · active not recruiting
NCT03800355 — Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03829306 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spanish Breast Cancer Research Group
Last refreshed: 13 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03829306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing